Skip to main content
SpringerLink
Log in

Prolifération des cancers du sein et biomarqueurs décisionnels en pratique RPC (RPC 2013)

  • Recommandations / Guidelines
  • Published:
Oncologie

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Albain KS, Barlow WE, Shak S, et al. (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11(1): 55–65

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7): 3983–3988

    Article  CAS  PubMed  Google Scholar 

  3. Azim Jr HA, Michiels S, Bedard PL, et al. (2012) Biology of breast cancer diagnosed in young women: pooled gene expression analysis from 3,522 patients. Ann Oncol 23(Suppl 2): ii19 (140-PR)

    Google Scholar 

  4. Barton S, Zabaglo L, A’Hern R, et al. (2012) Assessment of the contribution of the IHC4+C score to decision-making in clinical practice in early breast cancer. Br J Cancer 106(11): 1760–1765

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Beresford MJ, Stott D, Makris A (2008) Assessment of clinical response after two cycles of primary chemotherapy in breast cancer. Breast Cancer Res Treat 109(2): 337–342

    Article  PubMed  Google Scholar 

  6. Berruti A, Generali D, Kaufmann M, et al. (2011) International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr (43): 147–151

    Article  Google Scholar 

  7. Blohmer JU, Rezai M, Kummel S, et al. (2013) Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. J Med Econ 16(1): 30–40

    Article  CAS  PubMed  Google Scholar 

  8. Bullwinkel J, Baron-Luhr B, Ludemann A, et al. (2006) Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol 206(3): 624–635

    Article  CAS  PubMed  Google Scholar 

  9. Buyse M, Loi S, van’t Veer L, et al. (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98(17): 1183–1192

    Article  CAS  PubMed  Google Scholar 

  10. Cheang MC, Chia SK, Voduc D, et al. (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10): 736–750

    Article  CAS  PubMed  Google Scholar 

  11. Coudert B, Asselain B, Campone M, et al. (2012) Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. Oncologist 17(7): 900–909

    Article  CAS  PubMed  Google Scholar 

  12. Cronin M, Sangli C, Liu ML, et al. (2007) Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 53(6): 1084–1091

    Article  CAS  PubMed  Google Scholar 

  13. Cuzick J, Dowsett M, Pineda S, et al. (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 29(32): 4273–4278

    Article  PubMed  Google Scholar 

  14. Daidone MG, Silvestrini R (2001) Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. J Natl Cancer Inst Monogr 30: 27–35

    Article  PubMed  Google Scholar 

  15. Ding L, Ellis MJ, Li S, et al. (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291): 999–1005

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Dowsett M, Nielsen TO, A’Hern R, et al. (2011) Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst 103(22): 1656–1664

    Article  CAS  PubMed  Google Scholar 

  17. Dowsett M, Smith IE, Ebbs SR, et al. (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99(2): 167–170

    Article  CAS  PubMed  Google Scholar 

  18. Dumontet C, Krajewska M, Treilleux I, et al. (2010) BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Clin Cancer Res 16(15): 3988–3997

    Article  CAS  PubMed  Google Scholar 

  19. Ellis MJ, Tao Y, Luo J, et al. (2008) Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100(19): 1380–1388

    Article  CAS  PubMed  Google Scholar 

  20. Filipits M, Rudas M, Jakesz R, et al. (2011) A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17(18): 6012–6020

    Article  CAS  PubMed  Google Scholar 

  21. Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31(1): 13–20

    Article  CAS  PubMed  Google Scholar 

  22. Gerlinger M, Rowan A, Horswell S, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10): 883–892

    Article  CAS  PubMed  Google Scholar 

  23. Gokmen-Polar Y, Badve S (2012) Molecular profiling assays in breast cancer: are we ready for prime time? Oncology (Williston Park) 26(4): 350–357, 61

    Google Scholar 

  24. Goldhirsch A, Wood WC, Coates AS, et al. (2011) Strategies for subtypes —ealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8): 1736–1747

    Article  CAS  PubMed  Google Scholar 

  25. Guiu S, Michiels S, Andre F, et al. (2012) Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 23(12): 2997–3006

    Article  CAS  PubMed  Google Scholar 

  26. Habashy HO, Powe DG, Abdel-Fatah TM, et al. (2012) A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer. Histopathology 60(6): 854–863

    Article  PubMed  Google Scholar 

  27. Hall PS, McCabe C, Stein RC, Cameron D (2012) Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J Natl Cancer Inst 104(1): 56–66

    Article  PubMed  Google Scholar 

  28. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5): 646–674

    Article  CAS  PubMed  Google Scholar 

  29. Harris L, Fritsche H, Mennel R, et al. (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33): 5287–5312

    Article  CAS  PubMed  Google Scholar 

  30. Henry LR, Stojadinovic A, Swain SM, et al. (2009) The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 99(6): 319–323

    Article  CAS  PubMed  Google Scholar 

  31. Heppner G (1984) Tumor heterogeneity. Cancer Res 44: 2259–2265

    CAS  PubMed  Google Scholar 

  32. Hugh J, Hanson J, Cheang MC, et al. (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27(8): 1168–1176

    Article  CAS  PubMed  Google Scholar 

  33. Jankowitz RC, Cooper K, Erlander MG, et al. (2011) Prognostic utility of the breast cancer index and comparison to adjuvant! Online in a clinical case series of early breast cancer. Breast Cancer Res 13(5): R98

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Jerevall PL, Ma XJ, Li H, et al. (2011) Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 104(11): 1762–1769

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Jones RL, Salter J, A’Hern R, et al. (2009) The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 116(1): 53–68

    Article  CAS  PubMed  Google Scholar 

  36. Kelly CM, Warner E, Tsoi DT, et al. (2010) Review of the clinical studies using the 21-gene assay. Oncologist 15(5): 447–456

    Article  PubMed  Google Scholar 

  37. Klang SH, Hammerman A, Liebermann N, et al. (2010) Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health care organization. Value Health 13(4): 381–387

    Article  PubMed  Google Scholar 

  38. Knauer M, Cardoso F, Wesseling J, et al. (2010) Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Br J Cancer 103(12): 1788–1793

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Kondo M, Hoshi SL, Yamanaka T, et al. (2011) Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Res Treat 127(3): 739–749

    Article  PubMed  Google Scholar 

  40. Kronenwett R, Bohmann K, Prinzler J, et al. (2012) Decentral gene expression analysis: analytical validation of the Endopredict_genomic multianalyte breast cancer prognosis test. BMC Cancer 12: 456

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Laas E, Vataire AL, Aballea S, et al. (2012) Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France. J Med Econ 15(6): 1167–1175

    Article  PubMed  Google Scholar 

  42. Lamond NW, Skedgel C, Rayson D, et al. (2012) Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Res Treat 133(3): 1115–1123

    Article  PubMed  Google Scholar 

  43. Lo SS, Mumby PB, Norton J, et al. (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28(10): 1671–1676

    Article  PubMed  Google Scholar 

  44. Loi S, Haibe-Kains B, Desmedt C, et al. (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25(10): 1239–1246

    Article  CAS  PubMed  Google Scholar 

  45. Luporsi E, Andre F, Spyratos F, et al. (2012) Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 132(3): 895–915

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Mackey JR, Martin M, Pienkowski T, et al. (2013) Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 14(1): 72–80

    Article  CAS  PubMed  Google Scholar 

  47. Metzger Filho O, Ignatiadis M, Sotiriou C (2011) Genomic Grade Index: an important tool for assessing breast cancer tumor grade and prognosis. Crit Rev Oncol Hematol 77(1): 20–29

    Article  PubMed  Google Scholar 

  48. Mook S, Schmidt MK, Viale G, et al. (2009) The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 116(2): 295–302

    Article  CAS  PubMed  Google Scholar 

  49. Navin N, Kendall J, Troge J, et al. (2011) Tumour evolution inferred by single-cell sequencing. Nature 472(7341): 90–94

    Article  CAS  PubMed  Google Scholar 

  50. Nielsen TO, Parker JS, Leung S, et al. (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16(21): 5222–5232

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. Nik-Zainal S, Van Loo P, Wedge DC, et al. (2012) The life history of 21 breast cancers. Cell 149(5): 994–1007

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Paik S, Shak S, Tang G, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27): 2817–2826

    Article  CAS  PubMed  Google Scholar 

  53. Paik S, Tang G, Shak S, et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23): 3726–3734

    Article  CAS  PubMed  Google Scholar 

  54. Parker JS, Mullins M, Cheang MC, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8): 1160–1167

    Article  PubMed  Google Scholar 

  55. Penault-Llorca F, Goubar A, Raoelfils I, et al. (2012) Interpathologists discrepancies in Ki67 assessment in the PACS01 trial: an independent prognosis factor. J Clin Oncol 30(Suppl); abstr 543

    Google Scholar 

  56. Penault-Llorca F, Andre F, Sagan C, et al. (2009) Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27(17): 2809–2815

    Article  CAS  PubMed  Google Scholar 

  57. Perou CM, Jeffrey SS, van de Rijn M, et al. (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96(16): 9212–9217

    Article  CAS  PubMed  Google Scholar 

  58. Perou CM, Sorlie T, Eisen MB, et al. (2000) Molecular portraits of human breast tumours. Nature 406(6797): 747–752

    Article  CAS  PubMed  Google Scholar 

  59. Regan MM, Neven P, Giobbie-Hurder A, et al. (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12(12): 1101–1108

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Sheri A, Dowsett M (2012) Developments in Ki67 and other biomarkers for treatment decision-making in breast cancer. Ann Oncol 23(Suppl 10): x219–x227

    Article  PubMed  Google Scholar 

  61. Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101(21): 1446–1452

    Article  PubMed  Google Scholar 

  62. Sorlie T, Perou CM, Tibshirani R, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19): 10869–10874

    Article  CAS  PubMed  Google Scholar 

  63. Sotiriou C, Neo SY, McShane LM, et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100(18): 10393–10398

    Article  CAS  PubMed  Google Scholar 

  64. Sotiriou C, Wirapati P, Loi S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98(4): 262–272

    Article  CAS  PubMed  Google Scholar 

  65. Stadler ZK, Come SE (2009) Review of gene-expression profiling and its clinical use in breast cancer. Crit Rev Oncol Hematol 69(1): 1–11

    Article  PubMed  Google Scholar 

  66. Stephens PJ, Tarpey PS, Davies H, et al. (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486(7403): 400–404

    CAS  PubMed Central  PubMed  Google Scholar 

  67. Tang G, Cuzick J, Costantino JP, et al. (2011) Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol 29(33): 4365–4372

    Article  CAS  PubMed  Google Scholar 

  68. Teutsch SM, Bradley LA, Palomaki GE, et al. (2009) The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 11(1): 3–14

    Article  PubMed Central  PubMed  Google Scholar 

  69. Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23(28): 7212–7220

    Article  CAS  PubMed  Google Scholar 

  70. van de Vijver MJ, He YD, van’t Veer LJ, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25): 1999–2009

    Article  PubMed  Google Scholar 

  71. van Diest PJ, van der Wall E, Baak JP (2004) Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 57(7): 675–681

    Article  PubMed  Google Scholar 

  72. van’t Veer LJ, Dai H, van de Vijver MJ, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871): 530–536

    Article  Google Scholar 

  73. Varga Z, Diebold J, Dommann-Scherrer C, et al. (2012) How reliable is Ki-67 immunohistochemistry in grade II breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS ONE 7(5): e37379

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  74. Vataire AL, Laas E, Aballea S, et al. (2012) Cost-effectiveness of a chemotherapy predictive test. [Article in French] Bull Cancer 99(10): 907–914

    PubMed  Google Scholar 

  75. Viale G, Giobbie-Hurder A, Regan MM, et al. (2008) Prognostic and predictive value of centrally reviewed Ki-67 labelling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26(34): 5569–5575

    Article  PubMed  Google Scholar 

  76. Viale G, Regan MM, Mastropasqua MG, et al. (2008) Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100(3): 207–212

    Article  CAS  PubMed  Google Scholar 

  77. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8(10): 755–768

    Article  CAS  PubMed  Google Scholar 

  78. von Minckwitz G, Untch M, Loibl S (2013) Update on neoadjuvant/preoperative therapy of breast cancer: experiences from the German Breast Group. Curr Opin Obstet Gynecol 25(1): 66–73

    Article  Google Scholar 

  79. Weigel MT, Dowsett M (2010) Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 17(4): R245–R262

    Article  CAS  PubMed  Google Scholar 

  80. Yang M, Rajan S, Issa AM (2012) Cost effectiveness of gene expression profiling for early-stage breast cancer: a decision-analytic model. Cancer 118(20): 5163–5170

    Article  PubMed  Google Scholar 

  81. Yerushalmi R, Woods R, Ravdin PM, et al. (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2): 174–183

    Article  CAS  PubMed  Google Scholar 

Références électroniques

  1. Collège des économistes de la santé (2008) Guide méthodologique pour la mise en place d’une analyse d’impact budgétaire. Available from: http://www.ces-asso.org/docs/Rapport_AIB.pdf

    Google Scholar 

  2. Haute Autorité de santé (2011) Choix méethodologiques pour l’éevaluation économique à la HAS. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-11/guide_methodo_vf.pdf

    Google Scholar 

  3. Orphanet. Hémoglobinurie paroxystique nocturne 2012. Available from: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=FR&Expert=447.

  4. SOLIRIS 300MG/30ML SOL INJ FL 30ML —Monographie specialité. 2012. Available from: http://www.theriaque.org/apps/monographie/index.php?type=SP&id=21952&info=ADMIN

Download references

Author information

Authors and Affiliations

  1. oncologue médical, Villejuif, France

    F. André & S. Delaloge

  2. anatomo-pathologiste, Saint-Cloud, France

    J. -M. Guinebretière

  3. oncologue médical, Strasbourg, France

    T. Petit

  4. oncologue médical, Paris, France

    J. -Y. Pierga

  5. gynécologue, Paris, France

    D. Zarca

  6. médecin de Santé Publique, Paris, France

    K. Zarca

Authors
  1. F. André
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Delaloge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. -M. Guinebretière
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Petit
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. -Y. Pierga
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Zarca
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K. Zarca
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Cet article fait l’objet d’un tableau synthétique (DOI 10.1007/s10269-013-2352-4)

About this article

Cite this article

André, F., Delaloge, S., Guinebretière, J.M. et al. Prolifération des cancers du sein et biomarqueurs décisionnels en pratique RPC (RPC 2013). Oncologie 15, 594–604 (2013). https://doi.org/10.1007/s10269-013-2341-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-013-2341-3

Search

Navigation